Drug Profile
Cicletanine
Alternative Names: cycletanideLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Ipsen
- Developer Gilead Sciences; Navitas Pharma
- Class Antihypertensives; Pyridines; Small molecules
- Mechanism of Action Diuretics
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Pulmonary arterial hypertension
Most Recent Events
- 10 Mar 2016 Navitas Pharma and IndiPharm plan the phase I/II CHAMP trial for Hypertension in diabetes (Treatment-experienced) in USA and Malaysia (PO) (NCT02709031)
- 14 Jan 2016 Phase II development is ongoing in USA
- 14 Jan 2016 Cicletanine is available for licensing as of 14 Jan 2016 http://www.navitaspharma.com/